Trial · NCT07902596
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
NCT07902596, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma. Trials, record NCT07902596. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
- NCT number
- NCT07902596
- Status
- Not yet recruiting
- Enrollment
- 2,000 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Station-specific lymph node metastasis rates stratified by ycT and ycN categories | At definitive postoperative pathological assessment, generally within 30 days after gastrectomy | For each E, U, M, and L tumor-location cohort and each prespecified lymph node station, the metastasis rate will be calculated as the number of patients with pathologically confirmed metastasis at that station divided by the number of patients in whom that station was actually dissected and had an evaluable station-specific pathological record. Rates will be reported across the complete AJCC/UICC eighth-edition ycT and ycN categories. Stations not dissected or not verifiably recorded will be excluded from the station-specific denominator and will not be classified as negative. |
| Secondary | Station-specific lymph node metastasis rates stratified by ypT, ypN, and tumor regression grade | At definitive postoperative pathological assessment, generally within 30 days after gastrectomy | Station-specific metastasis rates will be estimated according to postoperative ypT category, ypN category, and standardized tumor regression grade, using only patients with evaluable station-specific pathological records. |
| Secondary | Numbers of examined and metastatic lymph nodes according to tumor location | At definitive postoperative pathological assessment, generally within 30 days after gastrectomy | The total number of examined lymph nodes and the total number of pathologically metastatic lymph nodes will be summarized for the E, U, M, and L tumor-location cohorts and by gastrectomy type. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902596
GET https://conductscience.org/api/trials/v1/NCT07902596/registered